Zelira Therapeutics (ZLDAF)
OTHER OTC:ZLDAF
ZLDAF Stock Chart & Stats
$0.21
-$0.03(-7.39%)
At close: 4:00 PM EST
$0.21
-$0.03(-7.39%)
Day’s Range― - ―
52-Week Range$0.20 - $0.48
Previous CloseN/A
Volume342.00
Average Volume (3M)189.00
Market Cap
$4.15M
Enterprise Value$8.08M
Total Cash (Recent Filing)$5.66K
Total Debt (Recent Filing)$2.14M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding11,897,155
10 Day Avg. Volume15
30 Day Avg. Volume189
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.13
Price to Sales (P/S)7702.11
P/FCF Ratio-1.03
Enterprise Value/Market Cap1.95
Enterprise Value/Revenue12.32K
Enterprise Value/Gross Profit-10.07
Enterprise Value/Ebitda-1.94
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Monetization StrategyThe company pursues multiple revenue paths—direct commercialization plus licensing and co-development—which is a durable business model advantage. Licensing can provide recurring, higher-margin B2B income and milestone cash inflows that reduce reliance on a single sales channel.
Specialized Cannabinoid Product FocusA clear, specialized product focus creates durable technical and commercial expertise in cannabinoid formulations and IP. This specialization supports differentiated products, targeted regulatory know‑how, and potential for partner interest in niche therapeutic and consumer segments.
Lean Operational FootprintA very small headcount implies low fixed operating overhead and operational flexibility. Over months this can extend runway, enable rapid pivots, and make the company a lower-cost partner for co-development or licensing arrangements compared with larger rivals.
Bears Say
Severe Revenue CollapseA near-total revenue collapse materially weakens the firm's ability to fund R&D, commercial launches, and partner obligations. Over the 2–6 month horizon, this reduces cash generation prospects, undermines negotiating leverage with partners, and raises execution risk.
Negative Shareholders' EquityNegative equity signals structural balance‑sheet weakness that limits borrowing capacity and financial flexibility. Persisting for months, it constrains strategic options, increases dependency on external financing, and can deter partners or suppliers requiring balance‑sheet strength.
Persistent Negative Cash FlowsOngoing negative operating and free cash flows deplete reserves and force reliance on external capital or asset monetization. Over the medium term this pressures R&D and commercialization plans, risks dilutive financings, and can impair the company’s ability to execute its strategic roadmap.
Zelira Therapeutics News
ZLDAF FAQ
What was Zelira Therapeutics’s price range in the past 12 months?
Zelira Therapeutics lowest stock price was $0.20 and its highest was $0.48 in the past 12 months.
What is Zelira Therapeutics’s market cap?
Zelira Therapeutics’s market cap is $4.15M.
When is Zelira Therapeutics’s upcoming earnings report date?
Zelira Therapeutics’s upcoming earnings report date is Sep 02, 2026 which is in 70 days.
How were Zelira Therapeutics’s earnings last quarter?
Currently, no data Available
Is Zelira Therapeutics overvalued?
According to Wall Street analysts Zelira Therapeutics’s price is currently Overvalued.
Does Zelira Therapeutics pay dividends?
Zelira Therapeutics does not currently pay dividends.
What is Zelira Therapeutics’s EPS estimate?
Zelira Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zelira Therapeutics have?
Zelira Therapeutics has 11,897,155 shares outstanding.
What happened to Zelira Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Zelira Therapeutics?
Currently, no hedge funds are holding shares in ZLDAF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zelira Therapeutics Stock Smart Score
Company Description
Zelira Therapeutics
Zelira Therapeutics Limited (ZLD.AX) is an Australian biopharmaceutical firm dedicated to the research, development, and commercialization of cannabinoid-derived medicines for a variety of medical conditions. Its product portfolio includes HOPE™ brand formulations, which are available in Pennsylvania and Louisiana, as well as Zenivol™, a cannabinoid-based medication designed to treat chronic insomnia. In addition to its prescription offerings, the company provides several over-the-counter (OTC) products. These include SprinJene™ for oral hygiene and RAF FIVE™ for dermatological applications. Zelira also markets ITURA™, an advanced topical relief cream formulated to target multiple symptoms such as numbness, tingling, muscle cramps, insensitivity, and pain associated with Peripheral Artery Disease and diabetes. Zelira maintains key strategic partnerships with academic and medical institutions, including Curtin University, the Telethon Kids Institute, the University of Western Australia, St. Vincent's Hospital, and the Children's Hospital of Philadelphia. Originally incorporated in 2003 as Zelda Therapeutics Limited, the company rebranded to Zelira Therapeutics Limited in December 2019. Its corporate headquarters are located in Perth, Australia.
Technical Analysis
Actinogen Medical
―
Tryptamine Therapeutics
―
Paradigm Biopharmaceuticals
―
Island Pharmaceuticals Ltd
―
Botanix Pharmaceuticals Limited
―